MétaCan
Menu
Back to cohort
Record W3164084589 · doi:10.1093/eurheartj/ehab234

The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study

2021· article· en· W3164084589 on OpenAlexfundno aff
Ewa A. Jankowska, Bridget‐Anne Kirwan, Mikhail Kosiborod, Javed Butler, Stefan D. Anker, Theresa A. McDonagh, Maria Dorobanţu, Jarosław Dróżdż, Gerasimos Filippatos, Andre Keren, Irakli Khintibidze, Hans Kragten, Felipe A. Martínez, Marco Metra, Davor Miličić, José Carlos Nicolau, Marcus Ohlsson, Alexander Parkhomenko, Domingo A. Pascual‐Figal, Frank Ruschitzka, David Sim, Hadi Skouri, Peter van der Meer, Basil S. Lewis, Josep Comín‐Colet, Stephan von Haehling, Alain Cohen‐Solal, Nicolas Danchin, Wolfram Doehner, Henry J. Dargie, Michael Motro, Tim Friede, Vincent Fabien, Fabio Dorigotti, Stuart Pocock, Piotr Ponikowski

Bibliographic record

VenueEuropean Heart Journal · 2021
Typearticle
Languageen
FieldMedicine
TopicErythropoietin and Anemia Treatment
Canadian institutionsnot available
FundersRelypsaEsperion TherapeuticsServierVifor PharmaSphingotec GmbHUniversität ZürichBiosense WebsterNovo NordiskDaiichi-SankyoImpulse DynamicsHamilton Health SciencesMundipharma Medical Company, BaselAbbott VascularRespicardiaZOLL Medical CorporationPfizerLivaNovaBoston Scientific CorporationEli Lilly and CompanyAstraZenecaCSL BehringHelsinnSanofiCardinal HealthAmgenEdwards Lifesciences
KeywordsMedicineHeart failureIntravenous ironQuality of life (healthcare)Iron deficiencyHealth related quality of lifeInternal medicineIntensive care medicineAnemiaNursingDisease

Abstract

fetched live from OpenAlex

AIMS: Patients with heart failure (HF) and iron deficiency experience poor health-related quality of life (HRQoL). We evaluated the impact of intravenous (IV) ferric carboxymaltose (FCM) vs. placebo on HRQoL for the AFFIRM-AHF population. METHODS AND RESULTS: The baseline 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12), which was completed for 1058 (535 and 523) patients in the FCM and placebo groups, respectively, was administered prior to randomization and at Weeks 2, 4, 6, 12, 24, 36, and 52. The baseline KCCQ-12 overall summary score (OSS) mean ± standard error was 38.7 ± 0.9 (FCM group) and 37.1 ± 0.8 (placebo group); corresponding values for the clinical summary score (CSS) were 40.9 ± 0.9 and 40.1 ± 0.9. At Week 2, changes in OSS and CSS were similar for FCM and placebo. From Week 4 to Week 24, patients assigned to FCM had significantly greater improvements in OSS and CSS scores vs. placebo [adjusted mean difference (95% confidence interval, CI) at Week 4: 2.9 (0.5-5.3, P = 0.018) for OSS and 2.8 (0.3-5.3, P = 0.029) for CSS; adjusted mean difference (95% CI) at Week 24: 3.0 (0.3-5.6, P = 0.028) for OSS and 2.9 (0.2-5.6, P = 0.035) for CSS]. At Week 52, the treatment effect had attenuated but remained in favour of FCM. CONCLUSION: In iron-deficient patients with HF and left ventricular ejection fraction <50% who had stabilized after an episode of acute HF, treatment with IV FCM, compared with placebo, results in clinically meaningful beneficial effects on HRQoL as early as 4 weeks after treatment initiation, lasting up to Week 24.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.014
Threshold uncertainty score0.330

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0030.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.019
GPT teacher head0.291
Teacher spread0.272 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations106
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Heart JournalSame topicErythropoietin and Anemia TreatmentFrench-language works237,207